Cumberland Pharmaceuticals Inc. filed a Form 8-K/A amendment on November 16, 2026, solely to furnish a press release dated October 26, 2026, that was inadvertently omitted from the original Form 8-K filed that same day regarding its ifetroban product candidate.

Key Highlights

  • Amendment purpose: The filing states its "sole purpose" is to furnish Exhibit 99.1, a press release dated October 26, 2026, which was "inadvertently omitted from the Original Report."
  • Underlying subject: The original October 26, 2026 report, which this amendment relates to, reported an update on the company's ifetroban product candidate.
  • No other changes: According to the filing, "this Amendment does not modify or update any disclosures in or exhibits to the Original Report" beyond adding the press release.
  • Exhibits filed: Exhibit 99.1 (press release dated October 26, 2026) and Exhibit 104 (Cover Page Interactive Data File) are listed in the filing.
  • Signed by: The amendment was signed by John Hamm, Chief Financial Officer of Cumberland Pharmaceuticals Inc., dated November 16, 2026.

Cumberland Pharmaceuticals Corrects October 8-K With Omitted Exhibit

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a Tennessee-based pharmaceutical company headquartered at 1600 West End Avenue, Suite 1300, Nashville, Tennessee, submitted this Amendment No. 1 on Form 8-K/A to address an administrative omission in a prior filing. According to the filing, the original Form 8-K was submitted on October 26, 2026, and covered an update related to the company's ifetroban product candidate.

The amendment discloses that Exhibit 99.1, described as a press release dated October 26, 2026, was "inadvertently omitted" from the original report. The filing states explicitly that the amendment's purpose is limited strictly to furnishing that exhibit. No financial statements, operational disclosures, or other content from the original report are altered or supplemented by this amendment, according to the filing's explanatory note.

The document lists two exhibits under Item 9.01: Exhibit 99.1, the October 26, 2026 press release, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document. The amendment was signed on behalf of the registrant by John Hamm in his capacity as Chief Financial Officer. Cumberland Pharmaceuticals Inc. is incorporated in Tennessee and carries Commission File Number 001-33637.

What Was Disclosed

Cumberland Pharmaceuticals filed an 8-K/A amendment on November 16, 2026, to attach a press release about its ifetroban product candidate that was left out of the original October 26, 2026 filing. No other disclosures in the original report were changed.